Last reviewed · How we verify
Proxymetacaine — Competitive Intelligence Brief
phase 1
Amine oxidase [flavin-containing] A, Sigma non-opioid intracellular receptor 1, Sodium channel protein type 10 subunit alpha
Ophthalmology
Small molecule
Live · refreshed every 30 min
Target snapshot
Proxymetacaine (Proxymetacaine) — Medical University of Silesia.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Proxymetacaine TARGET | Proxymetacaine | Medical University of Silesia | phase 1 | Amine oxidase [flavin-containing] A, Sigma non-opioid intracellular receptor 1, Sodium channel protein type 10 subunit alpha |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Proxymetacaine CI watch — RSS
- Proxymetacaine CI watch — Atom
- Proxymetacaine CI watch — JSON
- Proxymetacaine alone — RSS
Cite this brief
Drug Landscape (2026). Proxymetacaine — Competitive Intelligence Brief. https://druglandscape.com/ci/proxymetacaine. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing